Announcements
The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2017: Volume 22/ Issue 21 Article 4
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 22, Issue 21, 25 May 2017
Research article
Ireland, Croxford, Tosswill, Raghu, Davison, Hewitt, Simmons, and Taylor: Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses

+ Author affiliations


Citation style for this article: Ireland G, Croxford S, Tosswill J, Raghu R, Davison K, Hewitt P, Simmons R, Taylor G. Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses. Euro Surveill. 2017;22(21):pii=30539. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.21.30539

Received:20 July 2016; Accepted:02 February 2017


Introduction

The human T-lymphotropic viruses (HTLV), discovered in the early 1980s [1,2], have now infected an estimated 10 million people worldwide [3]. HTLV-1 is endemic in many tropical and subtropical regions, particularly the Caribbean, Iran, Melanesia, South America, southern India, southern Japan and West Africa [3]. In endemic areas, the distribution of infection varies, with seroprevalence among adults ranging between 0.1% and 30% [4]. In Europe and North America, HTLV-1 is predominately found among persons migrating from endemic areas, while HTLV-2 has been associated with injecting drug use [4].

Although the majority (ca 90%) of HTLV-1-infected individuals remain asymptomatic carriers, the other 10% will develop one or more of several diseases [5]: 2–6% will develop adult T-cell leukaemia/lymphoma (ATLL), a highly aggressive T-cell malignancy, while 2–3% develop a variety of chronic inflammatory syndromes, most notably HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) [6]. Other symptoms associated with HTLV infection include uveitis, thyroiditis, alveolitis, polymyositis and an impairment of immunity most strikingly associated with risk of strongyloidiasis observed in those HTLV-1 carriers exposed to Strongyloides stercoralis. There is no vaccine or effective treatment to reduce or eliminate HTLV viral load and treatments available for those who have malignant or inflammatory manifestations of HTLV infection are limited.

In endemic areas, HTLV is predominantly acquired through mother-to-child transmission (MTCT), primarily through breastfeeding [7], and through sexual contact, with male-to-female transmission approximately four times more likely to occur than female-to-male transmission [8]. However, there are no routine antenatal screening programmes in Europe. Blood transfusion has also been an important source of HTLV infection in some endemic areas, especially in Japan [4]. Blood, tissue and stem cell donations are currently routinely screened in a number of countries, including the United Kingdom (UK), while some blood services perform selective screening of first-time donors or rely on leucodepletion as an HTLV risk-reduction measure [9]. Other blood services, including many in Europe, have no screening programmes.

HTLV-1 testing was introduced in the UK in 1986 and routine testing of all blood donations was introduced in 2002 [10]. Surveillance by Public Health England (PHE; previously Health Protection Agency) was introduced in 1987 and enhanced surveillance in 2002 [11]. It is estimated that more than 22,000 persons are infected with HTLV in England and Wales [12] and the seroprevalence in pregnant women in the UK is 0.3 per 1,000 [13]. However, there is little information on patterns of HTLV testing [14], which will influence the rate of undiagnosed HTLV. Here we examine the patterns of HTLV antibody testing in England from 2008 to 2013, with data from the Sentinel Surveillance of Blood Borne Virus Testing (SSBBV), along with HTLV diagnoses in England and Wales over the 10-year period between 2004 and 2013 collected through the enhanced surveillance of new diagnoses of HTLV.

Methods

Data sources

Two data sources were used for our analysis: (i) SSBBV, to look at HTLV antibody testing in 2013 and changes in testing between 2008 and 2013, and (ii) the enhanced surveillance of new diagnoses of HTLV to describe the epidemiological and clinical characteristics of persons diagnosed with HTLV between 2004 and 2013 (Figure 1).

Figure 1

Flow of data within the Sentinel Surveillance of Blood Borne Virus Testing, England, 2008–2013, and the enhanced surveillance of HTLV, England and Wales, 2004–2013

/images/dynamic/articles/22803/16-00491-f1

HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus.

a Laboratories offering testing in 2013.

b Laboratories testing for HTLV throughout the period 2008 to 2013.

SSBBV collects information on tests for hepatitis A–E, HIV and HTLV, regardless of result, from 21 participating sentinel laboratories in England. Individuals are de-duplicated and linked to all their test results, using a combination of coded surname (soundex), first initial, date of birth, National Health Service (NHS) number and clinic number [15]. Alongside the test result, SSBBV records demographic information and the service requesting the test. Information on HTLV antibody testing has been collected by SSBBV since 2005, with 10 laboratories offering HTLV antibody testing in 2013, five of whom were testing for HTLV throughout the period 2008 to 2013. Coverage varies annually, but in 2013, SSBBV captured front line testing for these viruses by laboratories covering ca 40% of the general population of England and is broadly representative of laboratories providing routine and reference testing.

Enhanced surveillance of new diagnoses of HTLV in England and Wales has been conducted since 2002 by PHE [12,16]. In brief, blood samples are sent to the Virus Reference Department (VRD) in PHE Colindale for either antibody and/or confirmatory testing, by Western blot or PCR. Laboratory case reports of confirmed positive samples are provided to the HIV/sexually transmitted infection (STI) Surveillance Unit, who send an enhanced surveillance form to the referring clinician. The data collected include supplementary epidemiological and clinical information, including probable route of HTLV exposure, ethnicity, country of birth, probable country of infection and data on clinical symptoms at diagnosis. Enhanced forms are also received from NHS Blood and Transplant/PHE Epidemiology Unit for England and Wales when blood donors are found positive on routine donation screening. All data collected by PHE are pseudo-anonymised, with a soundex code and first initials collected instead of full names. Death reports on individuals who died from an HTLV-related illness are received from the Office of National Statistics and matched to the HTLV new diagnosis database using soundex code, date of birth and sex.

HTLV testing in 2013

Demographic and testing data for all individuals tested for HTLV antibodies in 2013 from 10 participating centres in England were extracted from SSBBV to give a snapshot of HTLV testing, as 2013 had the highest number of laboratories providing HTLV antibody tests for a full year. Where individuals had been tested more than once for HTLV antibodies, a reactive test was recorded over any negative or equivocal tests. Where all tests within 2013 were negative or equivocal, information from the most recent test was used.

Trends in HTLV testing: 2008 to 2013

To investigate trends, testing data for the period 2008–13 from the five sentinel laboratories with complete testing data for the 6-year period was used. Demographic and testing data for all individuals tested for HTLV antibodies between January 2008 and December 2013 were extracted from SSBBV. A cohort approach was used, with each individual recorded only once in each year tested. Where individuals had been tested more than once for HTLV antibodies in a year, a reactive test was recorded over any negative or equivocal tests. Where all tests in a year were negative or equivocal, information from the most recent test was used. Individuals who were reactive for HTLV antibodies were excluded from appearing in subsequent testing year cohorts.

HTLV testing in 2013 and trends in HTLV testing: 2008 to 2013

In both datasets, tests were linked to information on the location of the service requesting the test. Age at test was calculated using date of birth. Individuals younger than 1 year were excluded from the analysis, as a reactive result at that age may reflect maternal HTLV antibody status. Individuals with a reactive HTLV antibody test were considered to have confirmed HTLV-1 or HTLV-2 infection if a Western blot or PCR performed at the VRD at PHE, which provides the confirmatory HTLV diagnostics, was positive. Requesting services were grouped into primary care (which included testing in general practice (GP), genitourinary medicine (GUM), accident and emergency (A and E), occupational health, prisons and drug dependency units) and secondary care services, along with an additional category called ‘other’, which included tests requested by blood and stem cell banks, research studies and where requester information was not available.

Enhanced surveillance of new HTLV diagnoses: 2004 to 2013

Data for the years 2004 to 2013 were used for these analyses, based on reports received by end of October 2015. Numbers may rise as further reports are received, particularly for recent years.

Statistical analysis

Unless otherwise stated, HTLV in this paper refers to both HTLV-1 and HTLV-2. Stata SE (Version 13.1) was used, with Wilcoxen rank-sum tests to compare continuous variables and chi-squared and Fisher’s exact tests for categorical variables. A multivariate logistic regression, adjusted for age, sex, service type and year of test, was used to look at predictors of a reactive HTLV antibody test and confirmed HTLV diagnoses in those tested between 2008 and 2013. This dataset was used as more people were tested between 2008 and 2013 compared with the 2013 only dataset.

Joinpoint regression analysis was used to analyse changes in testing and positivity rates between 2008 and 2013, using Joinpoint Software (Version 4.3.1.0). Joinpoint identifies significant increases and decreases in testing and positivity rates over time, and whether there was a point at which a statistically significant change in the slope occurred during the period. The annual average percent change (APC) in testing numbers, with 95% confident intervals (95% CI), are reported. All proportions reported are excluding unknowns, and tests were considered statistically significant if the p value was lower than 0.05.

Results

HTLV testing in 2013

During 2013, 10 laboratories participating in sentinel surveillance reported HTLV testing in England, with 11,213 HTLV antibody tests conducted on 9,302 persons. Median age at testing was 45 years (interquartile range (IQR): 31–58 years), and men were older than women (49 vs 40 years; p < 0.001) (Table 1).

Table 1

Characteristics of persons testing for HTLV in 10 sentinel laboratories, England, 2013 (n = 9,302)

Patient characteristics n Reactive Confirmed positive
n % n %
Individuals 9,302 48 0.5 27 0.3
Sex
Male 4,562 22 0.5 10 0.2
Female 4,312 26 0.6 17 0.4
Unknown 428 0 0.0 0 0.0
Age (years)
1–29 1,901 8 0.4 2 0.1
30–44 2,528 8 0.3 2 0.1
45–59 2,480 22 0.9 16 0.6
≥ 60 2,094 10 0.5 7 0.3
Unknown 299 0 0.0 0 0.0
Service type
Primary 862 4 0.5 4 0.5
Secondary 7,597 39 0.5 22 0.3
Other 843 5 0.6 1 0.1

HTLV: human T-lymphotropic virus.

The majority (81.7%, 7,597/9,302) were tested within secondary care. Overall, the most common settings were haematology services (18.1%, 1,680/9,302), specialist renal services (13.4%, 1,250/9,302) and general medical or surgical departments (9.9%, 921/9,302). Among primary care settings, the most common for HTLV testing was GP with 265 tests (2.8% of all testing), followed by GUM services (2.7%, n = 247). In 2013, women’s services requested just 62 tests (0.7%), comprising 22 HTLV tests within antenatal care, 12 in gynaecological services, 18 in birthing and obstetric services and 10 in postnatal services. During 2013, there were 664,517 live births in England [17].

Overall, 0.5% (n = 48) of persons tested were reactive for HTLV antibodies in 2013. HTLV antibody-reactive women were older than men (44 vs 55 years; p < 0.001), and the proportion of reactive tests was highest in persons aged 45–59 years. More than half (n = 27) of those reactive for HTLV were confirmed HTLV-positive by the VRD at PHE. The age and sex distribution of those with a confirmed HTLV-positive result was similar to those reactive to HTLV antibodies.

Trends in HTLV testing: 2008 to 2013

Five sentinel laboratories consistently reported HTLV testing each year between 2008 and 2013, with 29,519 HTLV antibody tests performed on 27,206 persons (13,316 in men and 12,558 in women, of those for whom sex was known). Overall, the number of persons tested increased by an average of 9.5% (95% CI: 7.4–11.7) annually between 2008 and 2011, and by 22.2% (95% CI: 17.5–27.2) annually between 2011 and 2013 (Figure 2 and Table 2).

Figure 2

Trends in HTLV antibody testing in five sentinel laboratories, England, 2008–2013 (n = 29,519)

/images/dynamic/articles/22803/16-00491-f2

HTLV: human T-lymphotropic virus.

Table 2

Demographic characteristics and adjusted odds ratio of being reactive to HTLV antibodies and having a confirmed HTLV diagnosis, five participating sentinel centres, England, 2008–2013 (n = 29,519)

Patient characteristics All tested
(n = 29,519)
Reactive HTLV screen Confirmed HTLV diagnosis
Number
(n = 176)
aOR 95% CI p value Number
(n = 89)
aOR 95% CI p value
Age (aOR/10 year increase) 45 (33–59) a 52 (40–63) a 1.2 1.1–1.3 0.001 53 (42–64) a 1.4 1.2–1.5 < 0.001
Sex
Male 14,653 73 1 Ref 30 1 Ref
Female 13,524 102 1.7 1.2–2.3 0.001 59 2.4 1.6–3.8 < 0.001
Not reportedb 1,342 1 NA 0 NA
Service type
Primary 3,043 15 1 Ref 12 1 Ref
Secondary 23,142 152 1.2 0.7–2.0 0.6 75 0.6 0.3–1.2 0.1
Other 3,334 9 0.5 0.2–1.1 0.1 2 0.1 0.03–0.5 0.006
Year tested
2008 3,581 22 1 Ref 15 1 Ref
2009 3,977 32 1.3 0.8–2.3 0.3 14 0.9 0.4–1.9 0.8
2010 4,393 22 0.8 0.4–1.5 0.5 9 0.5 0.2–1.1 0.1
2011 4,719 37 1.3 0.8–2.2 0.3 16 0.9 0.4–1.8 0.7
2012 5,719 30 0.9 0.5–1.6 0.7 14 0.6 0.3–1.3 0.2
2013 7,130 33 0.8 0.5–1.4 0.5 21 0.8 0.4–1.6 0.5

aOR: adjusted odds ratio; CI: confidence interval; HTLV: human T-lymphotropic virus; NA: not applicable; Ref: reference value.

a Median and interquartile ranges.

b Persons of unknown sex were not included in the logistic regression.

The number tested each year between 2008 and 2013 increased by 17.8% (95% CI: 12.3–23.5) in women and by 10.7% (95% CI: 6.8–14.7) in men (Figure 2). Overall, the median age at test decreased from 47 years in 2008 to 43 years in 2013 (p < 0.001) and from 44 years to 38 years among women (p < 0.001); there was no significant change for men. While the number of persons screened for HTLV infection in primary care settings increased 157% overall, a result of more testing requested within GP and occupational health services, the APC was not significant (2008–10: 5.6%, 95% CI: −53.8 to 141 and 2010–13: 34.4%, 95% CI: −11.1 to 103). The number of people tested within secondary care increased 9.9% (95% CI: 6.7 to 13.2) annually between 2008 and 2013.

In the five sentinel laboratories, 0.6% of persons tested (n = 176) had a reactive HTLV antibody result between 2008 and 2013, with no significant difference in the proportion positive by year (p = 0.2). All other variables remained stable. The specialities that found the most number of persons reactive for HTLV were haematology (n = 53) and general medical and surgical wards (n = 20). Among those with an initially reactive HTLV antibody result, 50.6% (n = 89) were subsequently confirmed to have HTLV, a prevalence of 0.3%.

Predictors of a reactive HTLV screen and confirmed HTLV diagnosis

Using a multiple logistic regression (Table 2), the odds of testing reactive for HTLV antibodies did not change by year or between primary and secondary care, but increased for each 10-year increase in age (odds ratio (OR) = 1.2; 95% CI: 1.1–1.3) and for women compared with men (OR = 1.7; 95% CI: 1.2–2.3). These findings were similar for a confirmed HTLV diagnosis (Table 2), although the odds of being confirmed following a test in ‘other services’ (i.e. not specified) were lower than in primary care (OR = 0.1; 95% CI: 0.03–0.5).

HTLV diagnoses in England from enhanced surveillance 2004 to 2013

Between 2004 and 2013, 858 new HTLV diagnoses were reported to PHE in England and Wales, averaging 86 cases per year (range: 76–98) (Table 3).

Table 3

Demographic and clinical characteristics of persons reported to the enhanced surveillance of HTLV programme, England and Wales, 2004–2013 (n = 858)

Patient characteristics n %
Individuals 858 100.0
Sex
Male 302 35.2
Female 549 64.0
Unknown 7 0.8
Age (years)
1–29 81 9.4
30–44 183 21.3
45–59 308 35.9
≥ 60 284 33.1
Unknown 2 0.2
Ethnicity
White 102 11.9
Black Caribbean 328 38.2
Black African 66 7.7
Black other 7 0.8
Indian/Pakistani/Bangladeshi 19 2.2
Other/mixed 27 3.1
Unknown 309 36.0
HTLV type
HTLV-1 773 90.1
HTLV-2 40 4.7
Unknown 45 5.2
Exposure
Heterosexual sex and/or mother-to-child transmission 365 42.5
Other a 36 4.2
Unknown 457 53.3
HTLV-associated symptoms
Asymptomatic 267 31.1
HTLV symptoms 193 22.5
Non-HTLV symptoms 135 15.7
Unknown 263 30.7
Year of diagnosis
2004–08 406 47.3
2009–13 452 52.7
HIV co-infection 43 5.0
Deaths 96 11.2

HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus.

a Includes transfused blood, sex between men and people who inject drugs.

Where reported, more women were diagnosed with HTLV than men (64.5%; 549/851). Median age at diagnosis was 52 years (IQR: 42–66), with no difference between men and women (50 vs 53 years; p = 0.2). The majority of diagnoses were among persons of black Caribbean ethnicity (59.7%, 328/549), followed by white (18.6%, n = 102), black African (12.0%, n = 66), other/mixed (4.9%, n = 27), south Asian (3.5%, n = 19) and black other ethnicities (1.3%, n = 7). When compared with white individuals, persons of other/mixed and South Asian ethnicity were younger (49 vs 36 and 29 years, respectively; both p < 0.05), whereas persons of black Caribbean ethnicity were older (49 vs 53 years; p < 0.002). Where country of birth was reported (59.9%, n = 514), the majority of HTLV-positive persons of black African (51/56), black Caribbean (231/284), South Asian (14/17) and other/mixed ethnicity (17/25) were born abroad. Overall, 5.0% of persons diagnosed with HTLV (n = 43) were co-infected with HIV.

The majority of HTLV infections diagnosed, where type was reported, were HTLV-1 (95.1%, 773/813) and only 4.9% (n = 40) of persons were infected with HTLV-2. Most persons diagnosed with HTLV-1 were of black Caribbean origin (62.8%, 319/508 with known ethnicity), whereas most persons with HTLV-2 were of white ethnicity (n = 18).

Where reported (62.5%, n = 536), the most common reason for testing for HTLV was clinical symptoms (43.7%, n = 234), followed by blood donation (27.1%, n = 145). Persons diagnosed following blood donation were younger than those tested because of symptoms (41 vs 56 years; p < 0.001) and a higher proportion of women tested positive in the context of blood donation than men (30.7%, 109/355 v 20.2%, 36/178; p = 0.01). There was no difference by sex in the proportion of persons presenting with symptoms (41.7%, 148/355 vs 47.8%, 85/178; p = 0.1). Persons of black ethnicity (54.9%, 200/364) and those diagnosed with HTLV-1 (45.6%, 226/496) were most commonly diagnosed following the presentation of symptoms, whereas persons of white (46/98), other/mixed (13/23) and South Asian ethnicity (14/19) and those with HTLV-2 (10/19) were most commonly diagnosed when tested in the context of blood donation.

Probable route of infection was reported for 46.7% (n = 401) of persons between 2004 and 2013. Among those, just over a quarter were probably infected through heterosexual sex (27.7%, n = 111), another quarter (25.2%, n = 101) via MTCT, and 38.2% (n = 153) reported both MTCT and heterosexual contact. MTCT and heterosexual contact were the most common routes of probable infection regardless of ethnicity or sex, but men were more likely to report other transmission routes than women (16.1% vs 5.3%; p < 0.001) and almost all (9/10) persons with a probable infection following injecting drug use were of white ethnicity. A smaller proportion of persons infected with HTLV-2 reported a probable infection route of heterosexual contact and/or MTCT than those with HTLV-1 (57.9% vs 92.6%; p < 0.001), with injecting drug use accounted for the remaining infection in HTLV-2 (n = 8).

The majority of persons with symptoms reported were asymptomatic (44.9%, 267/595), 20.5% (n = 122) had ATLL, 15.0% (n = 89) had other or non-HTLV related symptoms, 11.9% (n = 71) had TSP/HAM and 7.7 (n = 46) had other malignancies/neurology (Table 4).

Table 4

Demographic and clinical characteristics of persons reported to the enhanced surveillance of HTLV programme, by symptoms, England and Wales, 2004–2013

Patient characteristics Asymptomatic ATLL TSP/HAM Other HTLV symptoms Non-HTLV symptoms Not reported
n % n % n % n % n % n %
Individuals 267 122 71 97 38 263
Median age (IQR) 44 (33–54) 59 (50–69) 53 (46–68) 60 (46–73) 57 (47–72) 55 (43–68)
Sex
Male 85 31.8 42 34.4 19 26.8 40 41.2 17 44.7 99 37.6
Female 181 67.8 79 64.8 52 73.2 57 58.8 21 55.3 159 60.5
Not Reported 1 0.4 1 0.8 0 0.0 0 0.0 0 0.0 5 1.9
Ethnicity
White 74 27.7 3 2.5 7 9.9 5 5.2 5 13.2 8 3.0
Black Caribbean 117 43.8 77 63.1 44 62.0 45 46.4 23 60.5 22 8.4
Black African 31 11.6 10 8.2 10 14.1 8 8.2 4 10.5 3 1.1
Black Other 3 1.1 3 2.5 0 0.0 1 1.0 0 0.0 0 0.0
Indian/Pakistani/Bangladeshi 16 6.0 0 0.0 1 1.4 1 1.0 0 0.0 1 0.4
Other/Mixed 18 6.7 1 0.8 0 0.0 2 2.1 2 5.3 4 1.5
Not Reported 8 3.0 28 23.0 9 12.7 35 36.1 4 10.5 225 85.6
Exposure
Heterosexual sex and/or mother to child transmission 189 70.8 54 44.3 45 63.4 38 39.2 25 65.8 14 5.3
Other a 26 9.7 1 0.8 1 1.4 4 4.1 2 5.3 2 0.8
Not Reported 52 19.5 67 54.9 25 35.2 55 56.7 11 28.9 247 93.9
HTLV type
HTLV-I 241 90.3 120 98.4 68 95.8 87 89.7 32 84.2 225 85.6
HTLV-II 16 6.0 0 0.0 0 0.0 4 4.1 3 7.9 17 6.5
Unknown 10 3.7 2 1.6 3 4.2 6 6.2 3 7.9 21 8.0
HIV Co-infection 16 6.0 5 4.1 2 2.8 8 8.2 6 15.8 6 2.3
Deaths 4 1.5 53 43.4 3 4.2 17 17.5 4 10.5 15 6.7

ATLL: T-cell leukaemia/lymphoma; HAM/TSP: HTLV-1-associated myelopathy/tropical spastic paraparesis; HTLV: human T-lymphotropic virus.

a Includes blood transfusion, sex between men and people who inject drugs.

Persons who were asymptomatic at diagnosis were younger than persons with ATLL and TSP/HAM (asymptomatic: 44 years vs ATLL: 55 years and TSP/HAM: 53 years, both p < 0.001). Regardless of ethnicity, most persons were asymptomatic at diagnosis, but almost all persons with ATLL were of black ethnicity (90/94). Where reported, a higher proportion of persons with HTLV-2 were asymptomatic than with HTLV-1 (69.6% vs 44.0%; p = 0.02).

Of all persons diagnosed between 2004 and 2013 in England and Wales, 96 (11.2%) are known to have died from HTLV-related illness. Deaths most commonly occurred in women (n = 57), persons of black Caribbean ethnicity (n = 47), persons with HTLV-1 (n = 89) and persons with ATLL (n = 53). Median time between HTLV diagnosis and death was 156 days (IQR: 28.5–324.5).

Discussion

An estimated 22,000 persons are infected with HTLV in England and Wales, yet each year an average of only 86 HTLV diagnoses are made. To explore why there is this discrepancy, we investigated HTLV testing patterns from sentinel laboratories in England. The numbers of persons tested for HTLV increased between 2008 and 2013, and the majority of HTLV tests occurred in secondary care. The biggest proportional increases in testing were seen among women and in primary care services but from a very small baseline, and testing in these settings remains uncommon. Although more testing occurred in men, women are more likely to have a reactive HTLV test and confirmed HTLV diagnosis.

This paper also updates the epidemiological picture of HTLV provided through enhanced surveillance since it was last described in 2002. The number of persons being diagnosed with HTLV remained constant over the 10-year period. The majority of persons diagnosed were female, of black Caribbean ethnicity and were born outside the UK. HTLV-1 remains the most common form of HTLV diagnosed in England and Wales and most patients were asymptomatic at diagnosis and infected through either heterosexual contact or MTCT. In contrast, the smaller fraction diagnosed with HTLV-2 were more likely to be white, asymptomatic and have a history of injecting drug use.

Our results collected through the enhanced surveillance are consistent with previous descriptions of HTLV-diagnosed persons in England and Wales [12,16], with similar risk factors, particularly by subtype. Compared with Spain, which has conducted similar surveillance, more cases were diagnosed per annum in England and Wales (89 vs 25) [18]. In addition, a higher proportion of cases in England and Wales had HTLV-1 when compared with Spain (90.1% vs 26.1%) and were linked to ATLL (20.5% vs 7.3%), whereas similar proportions were linked to HAM/TSP (England and Wales: 11.9%, Spain: 10.9%).

The vast majority of studies worldwide present data through blood donor testing, antenatal screening and enhanced surveillance, with limited information on general testing patterns. Sentinel surveillance of blood-borne virus testing presents a unique opportunity to gain an insight into where HTLV tests are being requested in England and reviewing changes in testing and prevalence estimates.

Like HIV and hepatitis, HTLV has a long latency period, and a person can be infected for many years before receiving a diagnosis or presenting symptoms. Therefore, it is likely that the vast majority of infections in England and Wales, estimated at 22,000 persons, remain undiagnosed [12]. The introduction of routine HTLV screening of tissue, blood and stem cell donations in 2002, alongside increased disease awareness, may have driven some of the observed increase in HTLV testing. However, the majority of tests still occurred in secondary care specialities where symptomatic patients are more likely to present or where blood, tissue and stem cell donation is common (haematology, renal services and ophthalmology). Therefore, these testing practices are unlikely to impact the undiagnosed proportion. Nevertheless, increased disease awareness, facilitated by the expansion of specialist HTLV clinics from one to four sites in England (London, Birmingham, Manchester and York), will ensure that testing for HTLV will be more widely considered outside of traditional settings.

Our testing data suggests potential missed opportunities for the prevention of maternal transmission of HTLV. While we observed some testing in antenatal, birthing and post-natal units, it is likely that much of this testing is being driven by the screening of tissue for storage and donation, rather than prevention of HTLV transmission, and primary care testing remains infrequent, implying that testing for HTLV infection is uncommon within sexual health services in England.

Prevalence of HTLV in some groups, particularly older individuals and women, was high. Higher positivity rates in older persons are likely to be due to low disease awareness and the long latency period where a person will remain asymptomatic before developing symptoms and being tested. Higher positivity rates in women are probably due to a higher prevalence in women overall, which may result from differences in the efficiency of HTLV transmission between male and female sexual partners, with transmission rates higher from HTLV-positive male partners [8,19]. Work to understand transmission within family settings in Japan estimated transmission rates from men to women to be as high as 60.8%, compared with 0.4% in female-to-male transmission [20], with similar outcomes in studies conducted in Jamaica and the United States [21,22]. In the UK, there are currently no seroprevalence studies with sufficient statistical power to assess differences by sex, however, the prevalence of HTLV in blood donors is higher in women [23]. In addition, these higher positivity rates may reflect differences in the presentation of females to care, with women more likely to present at healthcare settings earlier than men [24-26]. Lima et al. indicated that women in Brazil had faster disease progression than men [27].

The high rate of confirmation of HTLV infection following a reactive result in the initial test supports the high specificity of the currently available assays. This is important as there is concern, particularly in low prevalence regions, that even minimal lack of specificity places a large burden on diagnostic laboratories to investigate many false-negative results. Our finding that more than half of reactive antibody tests were confirmed positive is thus reassuring.

Although 72% of HTLV infections occurred in persons of black Caribbean or black African ethnicity, 94% of diagnoses of ATLL occurred within these ethnic groups. The Caribbean as well as western and southern Africa are endemic regions for HTLV infection and thus there is greater potential for mother-to-child HTLV transmission. HTLV-1 infection acquired perinatally or in infancy through breast-feeding has been associated with risk of ATLL, whereas HTLV-1 infection acquired in England and Wales is more likely to have been due to behaviour during adulthood. These data therefore support the assumption of ATLL risk and also draw attention to the need to consider HTLV-1 infection in any patient with a T-cell malignancy, but especially if they belong to a high-risk ethnic group.

There are two key limitations in our study. The first is the small number of persons with a positive HTLV screen and confirmed HTLV diagnosis. Despite our testing data indicating an increase in testing, with similar proportions testing positive for HTLV, we have not seen the number of persons reported to the enhanced surveillance of HTLV increase over the same time period. In addition, the small number of people diagnosed with HTLV prevented us from looking at demographic and clinical trends. Secondly, we were unable to look at trends in ethnicity in HTLV testing through the SSBBV testing database. It would have been particularly interesting to see whether particular groups are being targeted for testing in line with demographics, with persons of black Caribbean ethnicity representing the majority of those diagnosed with HTLV in England and Wales. Despite these limitations, enhanced surveillance of HTLV has high case ascertainment of persons diagnosed with HTLV in England and Wales, as all confirmatory tests are directed to PHEs VRD, ensuring that our sample is representative.

Since 2013, there have been significant changes to the surveillance of new diagnoses of HTLV, which has resulted in key clinical information being under-reported (< 30% completion rates), making comparison with more recent data problematic. Work is ongoing to improve the completeness of the dataset. However, we do not expect the characteristics of persons newly diagnosed with HTLV between 2014 and 2015 to differ significantly from those diagnosed between 2004 and 2013.

Although characteristics of those with a confirmed diagnosis of HTLV reported to the enhanced surveillance in England and Wales do not appear to have changed over the past 10 years, HTLV testing has increased in England. This increase occurred predominately through increased awareness of HTLV, associated with symptom presentation. Although there have been increases in testing, testing frequency in primary care services, including sexual health services, is still suboptimal and continued work is needed to ensure that HTLV is considered among those at greater risk, tackling the undiagnosed fraction and reducing transmission.


Acknowledgements

We wish to thank all the staff in participating Sentinel Surveillance of Blood Borne Virus Testing laboratories and the enhanced surveillance of HTLV programme, including Valerie Delpech, the IT, medical and scientific staff who supported these surveillance programme on an ongoing basis.

Conflict of interest

None declared.

Authors’ contributions

GT conceived the paper. KD, SC and PH developed the idea with GT. JT, SC and RR collected and processed the enhanced surveillance of HTLV data. GI extracted data from the sentinel surveillance of blood-borne virus testing, matched the two datasets and undertook the data analysis of both datasets, RS and GT supervised. GI drafted the paper and all authors provided critical input to the manuscript and approved all revisions.


References

  1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.Proc Natl Acad Sci USA. 1980;77(12):7415-9. DOI: 10.1073/pnas.77.12.7415 PMID: 6261256

  2. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia.Science. 1982;218(4572):571-3. DOI: 10.1126/science.6981847 PMID: 6981847

  3. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection.Front Microbiol. 2012;3:388. DOI: 10.3389/fmicb.2012.00388 PMID: 23162541

  4. Bangham CR. HTLV-1 infections.J Clin Pathol. 2000;53(8):581-6. DOI: 10.1136/jcp.53.8.581 PMID: 11002759

  5. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Volume 67: Human immunodeficiency viruses and human T-cell lymphotropic viruses. Lyon: IARC;1996. Available from: http://monographs.iarc.fr/ENG/Monographs/vol67/mono67.pdf

  6. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C,  et al.  Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology. 2003;61(11):1588-94. DOI: 10.1212/01.WNL.0000096011.92542.DA PMID: 14663047

  7. Fujino T, Nagata Y. HTLV-I transmission from mother to child.J Reprod Immunol. 2000;47(2):197-206. DOI: 10.1016/S0165-0378(00)00054-1 PMID: 10924751

  8. Stuver SO, Tachibana N, Okayama A, Shioiri S, Tsunetoshi Y, Tsuda K,  et al.  Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis. 1993;167(1):57-65. DOI: 10.1093/infdis/167.1.57 PMID: 8418183

  9. van Hoeven LR, Janssen MP, Rautmann G, European Committee on Blood Transfusion (EDQM). The collection, testing and use of blood and blood components in Europe. 2013 report. Brussels: European Directorate for the Quality of Medicines and HealthCare of the Council of Europe; 2016. Available from:https://www.edqm.eu/sites/default/files/the_collection_testing_and_use_of_blood_and_blood_components_in_europe_2013.pdf

  10. Simms I, Tosswill JH, Noone A, Morgan D. Surveillance of HTLV infection in England and Wales: 1986-1992.Commun Dis Rep CDR Rev. 1994;4(6):R65-9.PMID: 7519514

  11. Payne LJ, Tosswill JH, Taylor GP, Zuckerman M, Simms I. In the shadow of HIV-HTLV infection in England and Wales, 1987-2001.Commun Dis Public Health. 2004;7(3):200-6.PMID: 15481213

  12. Tosswill JH, Taylor GP, Tedder RS, Mortimer PP. HTLV-I/II associated disease in England and Wales, 1993-7: retrospective review of serology requests.BMJ. 2000;320(7235):611-2. DOI: 10.1136/bmj.320.7235.611 PMID: 10698878

  13. Ades AE, Parker S, Walker J, Edginton M, Taylor GP, Weber JN. Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study.BMJ. 2000;320(7248):1497-501. DOI: 10.1136/bmj.320.7248.1497 PMID: 10834889

  14. Public Health England. Annual report from the sentinel surveillance study of blood borne virus testing in England: data for January to December 2015. Health Protection Report. 10(24);2016. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/540332/hpr2416_bbvs.pdf

  15. Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ahmad F, Boxall E,  et al.  Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiol Infect. 2007;135(3):417-26. DOI: 10.1017/S0950268806006832 PMID: 16836798

  16. Dougan S, Smith A, Tosswill JC, Davison K, Zuckerman M, Taylor GP. New diagnoses of HTLV infection in England and Wales: 2002-2004.Euro Surveill. 2005;10(10):232-5.PMID: 16282645

  17. Office for National Statistics (ONS). 2013 Birth summary tables - England and Wales. London: ONS. [Accessed: 5 Jun 2016]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/datasets/birthsummarytables

  18. Treviño A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V, Spanish HIV-2/HTLV Study Group. The burden of neglected HIV-2 and HTLV-1 infections in Spain.AIDS Rev. 2015;17(4):212-9.PMID: 26616845

  19. Murphy EL, Figueroa JP, Gibbs WN, Brathwaite A, Holding-Cobham M, Waters D,  et al.  Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med. 1989;111(7):555-60. DOI: 10.7326/0003-4819-111-7-555 PMID: 2789009

  20. Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Okochi K. Intrafamilial transmission of adult T cell leukemia virus.J Infect Dis. 1986;154(5):851-7. DOI: 10.1093/infdis/154.5.851 PMID: 2877031

  21. Murphy EL, Figueroa JP, Gibbs WN, Brathwaite A, Holding-Cobham M, Waters D,  et al.  Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med. 1989;111(7):555-60. DOI: 10.7326/0003-4819-111-7-555 PMID: 2789009

  22. Kaplan JE, Khabbaz RF, Murphy EL, Hermansen S, Roberts C, Lal R, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;1;12(2):193-201.

  23. Public Health England (PHE). Supplementary data tables and figures 2014. NHS Blood and Transplant/Public Health England Epidemiology Unit. London: PHE; 2015.Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/474175/NHSBT_PHE_Annual_Review_Supplementary_Data_2014.pdf

  24. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services.J Fam Pract. 2000;49(2):147-52.PMID: 10718692

  25. Ladwig KH, Marten-Mittag B, Formanek B, Dammann G. Gender differences of symptom reporting and medical health care utilization in the German population.Eur J Epidemiol. 2000;16(6):511-8. DOI: 10.1023/A:1007629920752 PMID: 11049093

  26. Green CA, Pope CR. Gender, psychosocial factors and the use of medical services: a longitudinal analysis.Soc Sci Med. 1999;48(10):1363-72. DOI: 10.1016/S0277-9536(98)00440-7 PMID: 10369437

  27. Lima MA, Bica RB, Araújo AQ. Gender influence on the progression of HTLV-I associated myelopathy/tropical spastic paraparesis.J Neurol Neurosurg Psychiatry. 2005;76(2):294-6. DOI: 10.1136/jnnp.2004.035709 PMID: 15654060



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.